FDA Contributes Funds To Industry Post-Stenting Antiplatelet Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
The 20,000-patient dual antiplatelet therapy trial announced in October and slated to start enrolling patients this fall, likely will cost upward of $100 million, with most of the funds coming from industry.
You may also be interested in...
High Hopes For Stent Antiplatelet Therapy Trial
FDA, along with the four major drug-eluting stent manufacturers and four antiplatelet drug firms, are months away from launching an unprecedented $100 million, 20,000-patient trial to determine the optimum duration of dual antiplatelet therapy with drug-eluting stents
Confusion Over Anti-Clotting Therapy Hinders Drug-Eluting Stent Rebound
Blanket recommendations for one year of dual antiplatelet therapy for patients who receive drug-eluting stents may be the biggest cloud over the market for the devices, cardiologists suggest
FDA Eyes Upclassification, Labeling Guidance To Address Stapler Risks
The US agency sent a letter to health-care providers spotlighting its analysis of the increasing numbers of adverse events linked to surgical staplers and implantable staples, and its plans for a draft guidance on labeling and an advisory panel meeting to consider a 510(k) requirement for the products.